Outcome Analysis of the Use of Cerament
Cerament®
bone infection
bony defect
osteomyelitis
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
11 May 2022
11 May 2022
Historique:
received:
30
03
2022
revised:
03
05
2022
accepted:
10
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
Chronic osteomyelitis (OM) is a progressive but mostly low-grade infection of the bones. The management of this disease is highly challenging for physicians. Despite systematic treatment approaches, recurrence rates are high. Further, functional and patient-reported outcome data are lacking, especially after osseous defects are filled with bioresorbable antibiotic carriers. To assess functional and patient-reported outcome measures (PROM) following the administration of Cerament We conducted a retrospective study from 2015 to 2020, including all patients who received Cerament Twenty patients with Cierny and Mader type III OM were included in this study and followed up for 20.2 ± 17.2 months (95%CI 12.1-28.3). Ten of these patients needed at least one revision (2.0 ± 1.3 revisions per patient (95%CI 1.1-2.9) during the study period due to OM persistence or local wound complications. There were no statistically significant differences in functional scores or PROMs between groups. The use of Cerament
Sections du résumé
BACKGROUND
BACKGROUND
Chronic osteomyelitis (OM) is a progressive but mostly low-grade infection of the bones. The management of this disease is highly challenging for physicians. Despite systematic treatment approaches, recurrence rates are high. Further, functional and patient-reported outcome data are lacking, especially after osseous defects are filled with bioresorbable antibiotic carriers.
OBJECTIVE
OBJECTIVE
To assess functional and patient-reported outcome measures (PROM) following the administration of Cerament
METHODS
METHODS
We conducted a retrospective study from 2015 to 2020, including all patients who received Cerament
RESULTS
RESULTS
Twenty patients with Cierny and Mader type III OM were included in this study and followed up for 20.2 ± 17.2 months (95%CI 12.1-28.3). Ten of these patients needed at least one revision (2.0 ± 1.3 revisions per patient (95%CI 1.1-2.9) during the study period due to OM persistence or local wound complications. There were no statistically significant differences in functional scores or PROMs between groups.
CONCLUSION
CONCLUSIONS
The use of Cerament
Identifiants
pubmed: 35626362
pii: diagnostics12051207
doi: 10.3390/diagnostics12051207
pmc: PMC9139791
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Mater Sci Mater Med. 2020 Aug 25;31(9):80
pubmed: 32840717
J Orthop. 2016 Oct 26;14(1):45-52
pubmed: 27822001
Strategies Trauma Limb Reconstr. 2014 Nov;9(3):157-61
pubmed: 25540119
Am J Med. 2003 Jun 15;114(9):723-8
pubmed: 12829198
J Bone Jt Infect. 2019 May 21;4(3):146-154
pubmed: 31192115
BMC Infect Dis. 2018 Dec 7;18(1):635
pubmed: 30526540
Knee Surg Sports Traumatol Arthrosc. 2018 Jul;26(7):2059-2073
pubmed: 29026933
Clin Infect Dis. 1997 Dec;25(6):1303-9
pubmed: 9431368
J Bone Jt Infect. 2017 Oct 9;2(4):194-201
pubmed: 29119078
Bone Joint J. 2016 Apr;98-B(4):435-6
pubmed: 27037423
Ann Palliat Med. 2020 Jul;9(4):1821-1833
pubmed: 32279517
J Bone Jt Infect. 2016 Oct 1;1:59-64
pubmed: 28529855
Sci Rep. 2018 Oct 18;8(1):15384
pubmed: 30337629
J Bone Jt Infect. 2019 Aug 2;4(4):181-188
pubmed: 31555504
Heart. 2014 Feb;100(4):288-94
pubmed: 24186563
Clin Orthop Relat Res. 2017 Jan;475(1):160-167
pubmed: 27178041
J Orthop Surg Res. 2019 Nov 28;14(1):393
pubmed: 31779664
Bone Joint J. 2020 Nov;102-B(11):1587-1596
pubmed: 33135450
Foot (Edinb). 2019 Jun;39:22-27
pubmed: 30878011
J Orthop Trauma. 2002 Oct;16(9):622-7
pubmed: 12368641
J Bone Joint Surg Br. 2009 Aug;91(8):1106-9
pubmed: 19651846
J Bone Jt Infect. 2019 Mar 16;4(2):76-84
pubmed: 31011512
Cureus. 2022 Jan 5;14(1):e20969
pubmed: 35154948
Cells. 2021 Aug 11;10(8):
pubmed: 34440827
Bone Joint J. 2016 Sep;98-B(9):1289-96
pubmed: 27587534
Trials. 2019 Dec 9;20(1):693
pubmed: 31815653
J Bone Joint Surg Am. 2015 Oct 7;97(19):1628-34
pubmed: 26446970
J Bone Jt Infect. 2021 Jul 20;6(7):283-293
pubmed: 34345576
J Bone Jt Infect. 2021 Apr 28;6(5):151-163
pubmed: 34084705
J Orthop Surg Res. 2022 Feb 19;17(1):104
pubmed: 35183215
Am J Surg. 2004 Jul;188(1A Suppl):57-66
pubmed: 15223504
Bone Joint J. 2014 Jun;96-B(6):783-8
pubmed: 24891579
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S174-88
pubmed: 22588743
J Orthop Surg (Hong Kong). 2002 Jun;10(1):53-60
pubmed: 12401922
J Pediatr Orthop B. 2019 May;28(3):189-195
pubmed: 29851713
J Oral Maxillofac Surg. 2017 Jan;75(1):119-128
pubmed: 27450749
Clin Orthop Relat Res. 1993 Oct;(295):37-42
pubmed: 8403668